anti-IGSF8 monoclonal antibody GV20-0251

{
  "id": "MLC-T-ONC-010808",
  "term": "anti-IGSF8 monoclonal antibody GV20-0251",
  "field": "Oncology and biomedicine",
  "definition": "A human, Fc-attenuated immunoglobulin G1 (IgG1) monoclonal antibody targeting the immune checkpoint immunoglobulin superfamily member 8 (IGSF8; PGRL; PG regulatory-like protein, KCT-4, CD81 partner 3; LIR-D1; KASP; KAI/CD82 associated protein; EWI-2; Glu-Trp-Ile EWI motif-containing protein 2), with potential immune checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-IGSF8 monoclonal antibody GV20-0251 targets and binds to IGSF8 expressed on various immune cells, thereby preventing the binding of IGSF8 to beta 1 integrins and various tetraspanins. This inhibits IGSF8-mediated signaling and abrogates the IGSF8-mediated inhibition on immune activation. This may stimulate a T-cell-mediated immune response against cancer cells. IGSF8, a transmembrane adhesion protein and member of the Ig super family (IgSF), is an immune inhibitory receptor that plays a key role in cancer cell motility and suppression of T-cell proliferation and activation. It is involved in tumor cell immune evasion and the inhibition of immune responses.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-igsf8-monoclonal-antibody-gv20-0251/"
}